HpVac
A revolution in the first-line treatment of allergic diseases is under way
A revolution in the first-line treatment of allergic diseases is under way
HpVac is a biotechnology startup founded in 2016 and headquartered in Switzerland. The company's slogan, "A revolution in the first-line treatment of allergic diseases is under way," reflects its focus on developing a preventive and therapeutic first-line therapy against asthma, eczema, food allergies, and related allergic diseases. HpVac recently secured a $1.00M Seed Round investment on 01 February 2021. With its innovative approach to addressing prevalent health issues, HpVac is poised to make a significant impact in the biotechnology, healthcare, and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $1.00M | - | 01 Feb 2021 | |
| Seed Round | Fr.1.30M | - | 15 Aug 2018 | |
| Pre Seed Round | Fr.100.00K | - | 01 Jun 2016 |
No recent news or press coverage available for HpVac.
We care about your data, and we'd love to use cookies make your experience better.
